ALK and non-small cell lung carcinoma: ATLANTIC, an open-label phase 2 study, demonstrated the potential efficacy of an anti-PD-L1 monoclonal antibody, durvalumab, for third-line or later-line treatment of advanced NSCLC with EGFR mutation or ALK fusion [84].